Watson Health 's Watson Genomics is being added to Illumina 's TruSight Tumor 170, a tool that matches cancer patients with drugs that might help them. For doctors and hospitals, there are two big questions: Which genes do they sequence, and how do they analyze the resulting data? Watson , vice president of Watson Health , said that 170 Americans would benefit from having their tumour DNA sequenced, but fewer than 10% do. The aim of the partnership is to make it easier for hospitals to get started with DNA sequencing. The DNA sequencer analyses the 170 genes in the tumour and within minutes , Steve Harvey produces a report indicating whether a medicine currently available might prove effective.
Watson Health 's Watson Genomics is being added to Illumina 's TruSight Tumor 170, a tool that matches cancer patients with drugs that might help them. Watson , vice president of Watson Health , said that 170 Americans would benefit from having their tumour DNA sequenced, but fewer than 10% do. The aim of the partnership is to make it easier for hospitals to get started with DNA sequencing. The DNA sequencer analyses the 170 genes in the tumour and within minutes , Steve Harvey produces a report indicating whether a medicine currently available might prove effective.